Bavarian Nordic’s MVA-BN vaccine showed equivalent antibody response and safety between teenagers and adults in an NIH study.

The company’s keratoconus medication, Epioxa, was effective in a Phase III trial, with plans to file for submission with the ...

The latest round of layoffs will see Sage reduce 33% of its total workforce. Credits: Wirestock Creators/Shutterstock.com ...

Acadia Pharmaceuticals has received marketing authorisation from Health Canada for DAYBUE (trofinetide) to treat Rett ...

Lexicon Pharmaceuticals has entered a licensing agreement with Viatris to commercialise sotagliflozin outside the US and ...

After a hearing held on 25 September 2024, the European Patent Office (EPO) affirmed bit.bio’s claim against an anonymous ...

Synedgen has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop ...

UroGen Pharma has received the NDA acceptance from the US FDA for UGN-102 (mitomycin) to treat bladder cancer.

The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM: US, France, Germany, Italy, Spain, ...

A new generation of remote monitoring devices in Scotland is helping to reduce the burden on healthcare systems and improve ...

Seltorexant is one of J&J’s most promising neuroscience candidates. The human orexin-2 receptor selective agonist produced ...

Pfizer has announced the approval of HYMPAVZI (marstacimab-hncq) by the US Food and Drug Administration (FDA) for routine ...